Volume 90%
Press shift question mark to access a list of keyboard shortcuts
Keyboard Shortcuts
Play/PauseSPACE
Increase Volume
Decrease Volume
Seek Forward
Seek Backward
Captions On/Offc
Fullscreen/Exit Fullscreenf
Mute/Unmutem
Seek %0-9
00:00
00:00
00:00
 

Chapters

Transcript

 

I'm Melissa Murray, I'm an assistant professor at the Mayo Clinic in Jacksonville, Florida. And we recently investigated the role of two proteins implicated in Alzheimer's disease, amyloid and tau. These two proteins have been studied for the last 25 years, but part of this study has been much debated which one plays the biggest part with respect to the cognitive decline. And found that in fact tau, drives the cognitive dysfunction.

Secondly we looked at amyloid imaging and found that the value of amyloid imaging, remains quite viable in the clinical setting. Especially with tau imaging on the horizon. With the two, both tau and amyloid imaging, we have the opportunity to diagnose and rule out multiple disorders. Our findings support a focused role on tau, whether through imaging, therapeutics, or modulation of the proteins effects on the progression of the disease.

Video

Mayo Clinic study of thousands of brains reveals tau as driver of Alzheimer's disease

By examining more than 3,600 postmortem brains, researchers at Mayo Clinic's campuses in Jacksonville, Florida, and Rochester, Minnesota, have found that the progression of dysfunctional tau protein drives the cognitive decline and memory loss seen in Alzheimer's disease. Amyloid, the other toxic protein that characterizes Alzheimer's, builds up as dementia progresses, but is not the primary culprit, they say.

The findings, published in Brain, offer new and valuable information in the long and ongoing debate about the relative contribution of amyloid and tau to the development and progression of cognitive dysfunction in Alzheimer's, says the study's lead author, Melissa E. Murray, Ph.D., a neuroscientist at Mayo Clinic in Jacksonville, Florida.

ADVERTISEMENT

Related Videos